Literature DB >> 23378275

Neural and immune mechanisms in the pathogenesis of Parkinson's disease.

Fabio Blandini1.   

Abstract

Although almost 50 years have passed since impaired dopaminergic transmission was identified as the main neurochemical defect in Parkinson's disease (PD), the cause of the disease remains unknown. A restricted number of biological mechanisms are likely to contribute to the process of cell death in the nigrostriatal pathway. These mechanisms include mitochondrial defects and enhanced formation of reactive oxygen species--leading to oxidative damage--and abnormal protein aggregation. In addition to or, possibly, intermingled with these mechanisms of neuronal damage there is another crucial factor: neuroinflammation. The inflammatory response associated with cell loss in the dopaminergic nigrostriatal tract and, more in general, the role of immune mechanisms are increasingly recognized in PD pathogenesis. Neuroinflammatory changes have been repeatedly demonstrated, in both neurotoxic and transgenic animal models of PD, as well as in PD patients. Transgenic models based on α-synuclein overexpression, in particular, have provided crucial insights into the correlation between this protein and the dichotomous response that microglia can activate, with the polarization toward a cytotoxic (M1) or cytoprotective (M2) phenotype. Full understanding of such mechanisms may set the ground for a fine tuning of the neuroinflammatory process that accompanies and sustains neurodegeneration, thereby opening new therapeutic perspectives for PD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23378275     DOI: 10.1007/s11481-013-9435-y

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  131 in total

1.  The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease.

Authors:  B Mirza; H Hadberg; P Thomsen; T Moos
Journal:  Neuroscience       Date:  2000       Impact factor: 3.590

2.  Adhesion molecules as potential targets for neuroprotection in a rodent model of Parkinson's disease.

Authors:  Marie-Therese Armentero; Giovanna Levandis; Eleonora Bazzini; Silvia Cerri; Cristina Ghezzi; Fabio Blandini
Journal:  Neurobiol Dis       Date:  2011-06-12       Impact factor: 5.996

3.  6-Hydroxydopamine-induced alterations in blood-brain barrier permeability.

Authors:  P M Carvey; C H Zhao; B Hendey; H Lum; J Trachtenberg; B S Desai; J Snyder; Y G Zhu; Z D Ling
Journal:  Eur J Neurosci       Date:  2005-09       Impact factor: 3.386

4.  Microglial response to 6-hydroxydopamine-induced substantia nigra lesions.

Authors:  H Akiyama; P L McGeer
Journal:  Brain Res       Date:  1989-06-12       Impact factor: 3.252

5.  The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein.

Authors:  Amy B Manning-Bog; Alison L McCormack; Jie Li; Vladimir N Uversky; Anthony L Fink; Donato A Di Monte
Journal:  J Biol Chem       Date:  2001-11-13       Impact factor: 5.157

6.  Transforming growth factor-beta 1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson's disease.

Authors:  M Mogi; M Harada; T Kondo; H Narabayashi; P Riederer; T Nagatsu
Journal:  Neurosci Lett       Date:  1995-06-30       Impact factor: 3.046

Review 7.  The 6-hydroxydopamine model: news from the past.

Authors:  Fabio Blandini; Marie-Therese Armentero; Emilia Martignoni
Journal:  Parkinsonism Relat Disord       Date:  2008-07-02       Impact factor: 4.891

Review 8.  α-Synuclein and dopamine at the crossroads of Parkinson's disease.

Authors:  Lara Lourenço Venda; Stephanie J Cragg; Vladimir L Buchman; Richard Wade-Martins
Journal:  Trends Neurosci       Date:  2010-10-18       Impact factor: 13.837

9.  Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro.

Authors:  Jacqueline Burré; Manu Sharma; Theodoros Tsetsenis; Vladimir Buchman; Mark R Etherton; Thomas C Südhof
Journal:  Science       Date:  2010-08-26       Impact factor: 47.728

Review 10.  Visualising microglial activation in vivo.

Authors:  Richard B Banati
Journal:  Glia       Date:  2002-11       Impact factor: 8.073

View more
  48 in total

1.  Lipolysaccharide-Induced Neuroinflammation Is Associated with Alzheimer-Like Amyloidogenic Axonal Pathology and Dendritic Degeneration in Rats.

Authors:  Xiaohua Deng; Meili Li; Weiming Ai; Lixin He; Dahua Lu; Peter R Patrylo; Huaibin Cai; Xuegang Luo; Zhiyuan Li; Xiaoxin Yan
Journal:  Adv Alzheimer Dis       Date:  2014-06

2.  The Second Insubria Autumn School on Neuroimmune Pharmacology: Repurposing Established Drugs for Novel Indications.

Authors:  Marco Cosentino; Franca Marino
Journal:  J Neuroimmune Pharmacol       Date:  2015-12-16       Impact factor: 4.147

Review 3.  Targeting specific cells in the brain with nanomedicines for CNS therapies.

Authors:  Fan Zhang; Yi-An Lin; Sujatha Kannan; Rangaramanujam M Kannan
Journal:  J Control Release       Date:  2015-12-11       Impact factor: 9.776

4.  Downregulation of DEC1 contributes to the neurotoxicity induced by MPP+ by suppressing PI3K/Akt/GSK3β pathway.

Authors:  Zhu Zhu; Yu-Wen Wang; Ding-Hao Ge; Ming Lu; Wei Liu; Jing Xiong; Gang Hu; Xiao-Ping Li; Jian Yang
Journal:  CNS Neurosci Ther       Date:  2017-07-21       Impact factor: 5.243

Review 5.  Microglial M1/M2 polarization and metabolic states.

Authors:  Ruben Orihuela; Christopher A McPherson; Gaylia Jean Harry
Journal:  Br J Pharmacol       Date:  2015-05-11       Impact factor: 8.739

6.  Neuroprotective effects of roflumilast against quinolinic acid-induced rat model of Huntington's disease through inhibition of NF-κB mediated neuroinflammatory markers and activation of cAMP/CREB/BDNF signaling pathway.

Authors:  Priyanka Saroj; Yashika Bansal; Raghunath Singh; Ansab Akhtar; Rupinder Kaur Sodhi; Mahendra Bishnoi; Sangeeta Pilkhwal Sah; Anurag Kuhad
Journal:  Inflammopharmacology       Date:  2021-01-31       Impact factor: 4.473

7.  The first Insubria autumn school on neuroimmunopharmacology: challenging paradigms beyond boundaries.

Authors:  Marco Cosentino; Howard E Gendelman
Journal:  J Neuroimmune Pharmacol       Date:  2013-02-12       Impact factor: 4.147

8.  Vitamin D Treatment Attenuates Neuroinflammation and Dopaminergic Neurodegeneration in an Animal Model of Parkinson's Disease, Shifting M1 to M2 Microglia Responses.

Authors:  Rosa Calvello; Antonia Cianciulli; Giuseppe Nicolardi; Francesco De Nuccio; Laura Giannotti; Rosaria Salvatore; Chiara Porro; Teresa Trotta; Maria Antonietta Panaro; Dario Domenico Lofrumento
Journal:  J Neuroimmune Pharmacol       Date:  2016-12-16       Impact factor: 4.147

Review 9.  Estrogens, Neuroinflammation, and Neurodegeneration.

Authors:  Alessandro Villa; Elisabetta Vegeto; Angelo Poletti; Adriana Maggi
Journal:  Endocr Rev       Date:  2016-05-19       Impact factor: 19.871

Review 10.  The Role of Sex and Sex Hormones in Neurodegenerative Diseases.

Authors:  Elisabetta Vegeto; Alessandro Villa; Sara Della Torre; Valeria Crippa; Paola Rusmini; Riccardo Cristofani; Mariarita Galbiati; Adriana Maggi; Angelo Poletti
Journal:  Endocr Rev       Date:  2020-04-01       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.